Status:
COMPLETED
Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
Lead Sponsor:
Asokumar Buvanendran
Collaborating Sponsors:
Pfizer
Conditions:
PAIN
Eligibility:
All Genders
55-75 years
Phase:
PHASE3
Brief Summary
This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgi...
Detailed Description
Gabapentin and the related more potent compound pregabalin have been shown to reduce postoperative pain in animal models (1). Pregabalin given before and after surgery reduced opioid use following spi...
Eligibility Criteria
Inclusion
- History of osteoarthritis
- Subjects who can understand and communicate in English
Exclusion
- Younger than 55 years or older than 75 years.
- American Society of Anesthesiologists physical status IV
- Prior use of pregabalin or gabapentin will not be an exclusionary criterion; however patients will have been withdrawn from these medications at least 14 days before surgery
- Patients who are currently enrolled in another investigational study.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00729690
Start Date
August 1 2008
End Date
July 1 2011
Last Update
December 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612